Duquesne Family Office is a New York, New York-based family office. Value Add VC tracks 2 companies Duquesne Family Office has invested in and 2 venture rounds it took part in (0 as lead).
Duquesne Family Office key facts (as of )
| Fact | Value | Source |
|---|---|---|
| Headquarters | New York, New York, USA | SEC EDGAR Schedule 13G, November 7, 2026 |
| Founded | 2010 | The Motley Fool, November 7, 2026 |
| Type | Family office | Value Add VC classification |
| Partners and team | Stanley Druckenmiller (Chairman and CEO); Sue Meng (General Counsel) | Partners and team section on this page (each name cites its source) |
| Venture rounds tracked | 2 (led 0, joined 2) 2 in the last 12 months | Recent deals table on this page (each round cites its source) |
| Portfolio companies tracked | 2 | Portfolio list on this page |
Duquesne Family Office overview
Duquesne Family Office LLC is a Delaware limited liability company that files with the SEC jointly with investor Stanley Druckenmiller.[1] Its principal business office is at 40 West 57th Street in New York.[1]
Recent deals we track
2Track record: led 0 and participated in 2 of 2 tracked venture rounds · 2 in the last 12 months
| Date | Company | Event | Role | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | Precision Neuroscience | Series D | Participated | $250M | ~$1B | Pershing SquareLeadunverifiedAckman Oxman InstituteLeadunverifiedDuquesne Family OfficeunverifiedB CapitalARK InvestInvusMubadala CapitalMirae Asset CapitalKorea Investment PartnersHitachi VenturesJSL Health Capital | GlobeNewswire |
| Sep 9, 2026 | Fab2 | Series A | Participated | $500M | $3.7B | Fundomo ManagementLeadParadigmDuquesne Family OfficeunverifiedMaverick SiliconStepStone GroupProtagonistCorner CapitalUDC VenturesNaval Ravikant | WOWTALE |
Is something wrong on this page?
About Duquesne Family Office
Duquesne Family Office was founded in 2010 and is headquartered in New York, New York, USA.[The Motley Fool][SEC EDGAR Schedule 13G] Its partners and team include Stanley Druckenmiller (Chairman and CEO) and Sue Meng (General Counsel).[SEC EDGAR Schedule 13G][SEC EDGAR Form 13F-HR]
Duquesne Family Office partners and team
2- Stanley Druckenmiller · Chairman and CEO (SEC EDGAR Schedule 13G)
- Sue Meng · General Counsel (SEC EDGAR Form 13F-HR)
At a glance
Duquesne Family Office appears in 2 funding rounds tracked by ValueAddVC since 2026. Its most recent tracked deal was Precision Neuroscience's $250M Series D round (Sep 24, 2026).
Duquesne Family Office profile
written 2026-11-07Duquesne Family Office is Stanley Druckenmiller's New York family office, visible mainly through SEC filings and a few private rounds.
What Duquesne Family Office does
Duquesne Family Office LLC is a Delaware limited liability company with its principal business office in New York, according to its Schedule 13G filings. Stanley Druckenmiller, its Chairman and Chief Executive Officer, controls it and files jointly with it.[1]
Duquesne Family Office LLC says in a 2024 Schedule 13G that neither it nor Druckenmiller owns the reported common stock directly. Under a management agreement, the filing says, the firm maintains investment and voting power over securities held by certain investment funds it manages.[1]
Duquesne Family Office leaves most of its public record in SEC filings on listed securities. The EDGAR listing opened for this profile shows quarterly Form 13F-HR holdings reports, the latest dated August 14, 2026, and Schedule 13G statements on individual stakes.[2],[1],[3]
No Duquesne Family Office website, strategy statement or team page turned up in the sources opened here, so the firm's own account of its approach is missing. Its private-company activity appears only through other parties' announcements, covered below.[2]
History
Duquesne Family Office was launched in 2010 by Stanley Druckenmiller, according to the Motley Fool. The Fool adds that Druckenmiller, a Pittsburgh native, named the firm after a park in his hometown.[4]
Duquesne Capital was Druckenmiller's predecessor firm, created in 1981 with $800,000, according to the Motley Fool. He shut it down in 2010, citing the heavy personal costs of managing what the Fool calls a $12 billion fund, and opened the family office that year.[4]
Funds
Duquesne Family Office LLC names no fund and gives no assets-under-management figure in the filings opened for this profile. Its 2024 Schedule 13G refers only to certain investment funds it manages.[1]
The Motley Fool puts the firm at a $4.07 billion fund at the end of the second quarter of 2025. That is the Fool's figure, not a number the firm has stated. The Form 13F for June 30, 2026 reports 95 table entries and a value total of 5,210,860. Natera's line shows 864,923 against 3,186,306 shares, which only fits values in thousands of dollars. Either way the 13F covers listed securities and options, not private holdings, so it is not assets under management.[4],[5],[3],[6]
People
Stanley Druckenmiller is Chairman and Chief Executive Officer of Duquesne Family Office LLC and signs its Schedule 13G statements. The 2024 filing says he controls the firm in that capacity.[1],[6]
Stanley Druckenmiller joined George Soros's Quantum Fund in 1988 while still operating Duquesne Capital, and left Quantum in 2000, according to the Motley Fool.[4]
Sue Meng is named as General Counsel on the cover of Duquesne Family Office LLC's Form 13F-HR for June 30, 2026, which she signed on August 14, 2026. An October 30, 2025 release carried by The Quantum Insider calls her Managing Director at Duquesne Family Office and says she joined Q.ANT's advisory board as an observer. The two documents give different titles.[5],[7],[3],[6]
Portfolio and notable investments
Duquesne Family Office LLC reported 95 line items in its Form 13F-HR for the quarter ended June 30, 2026. Natera carries the largest figure in the information table's value column, on 3,186,306 shares. The table does not show private holdings.[3],[6]
Other lines in the same table include 3,102,880 shares of STMicroelectronics, 589,680 shares of Taiwan Semiconductor Manufacturing ADS, 3,138,897 shares of YPF ADR, 541,600 shares of Amazon and 336,300 shares of Alphabet. The filing text does not state the unit of its value column, so no dollar totals are given here.[3],[6]
Duquesne Family Office LLC's 13F is not a long-only list. It carries separate call lines, including 459,300 shares of Amazon, 126,000 of Tesla and 1,350,000 of Insmed, the last alongside 1,424,690 Insmed common shares.[3],[6]
Daktronics shows a gap the filings do not close. A Schedule 13G for an event dated May 2, 2024 reported 2,493,605 shares, or 5.4% of the class. The amendment, for an event dated September 22, 2025, reports zero shares and zero percent. The June 30, 2026 Form 13F nonetheless lists 1,123,109 Daktronics shares.[1],[3],[8],[6]
Two 2026 Schedule 13G filings show larger stakes in small public companies. Duquesne reported 12.7% of the class in Guardian Metal Resources PLC for an event dated March 31, 2026, in a filing signed September 14, 2026. For BBB Foods, it reported 5% for an event dated January 23, 2026. A second BBB Foods filing signed July 29, 2026 reports 3.7% for an event dated June 30, 2026, which is below the 5% line.[9],[6],[10],[11],[12],[1]
Duquesne Family Office took part in the second closing of Q.ANT's Series A, according to a release carried by The Quantum Insider on October 30, 2025. The release puts Q.ANT's total funding at $80 million and names Cherry Ventures, UVC Partners and imec.xpand as current lead investors. It gives no amount for Duquesne's investment.[7],[6]
Duquesne Family Office was named as an additional investor in Precision Neuroscience's $250 million Series D, which Pulse 2.0 reported on September 27, 2026. Pershing Square, the Ackman Oxman Institute and an undisclosed life sciences fund co-led the round, and total funding reached $430 million. Institutional Investor says Duquesne participated for the second time. Neither article gives Duquesne's check size.[13],[14],[6]
Institutional Investor reported on October 21, 2026 that Duquesne Family Office participated in Fab2's $500 million Series A, a round it says valued the company, formerly Atomic Semi, at $3.7 billion. The article does not say how much Duquesne put in.[14],[6],[10]
What founders should know
Duquesne has no website or public statement of stage, sector or check size in the sources opened. In the three private rounds above, it is named among additional participants rather than as a lead, and none of the sources gives its check size. Its filings show a listed-equity book of 95 entries, so private rounds look like a small part of its activity. Most of what is public comes from co-investors' releases, so a founder is more likely to meet Duquesne through a lead investor than through a direct pitch.[5],[13],[14],[7],[3],[6]
Strategy
Recent changes
- Sep 24, 2026Sep 24, 2026Invested in Precision Neuroscience (Series D, $250M) GlobeNewswire
- Sep 9, 2026Sep 9, 2026Invested in Fab2 (Series A, $500M) WOWTALE
Portfolio
2 totalSector / Stage Activity
Co-Investors
11Similar Firms
overlapping sector, stage or regionValue Add Research
Latest Pulse
- Oct 15, 2026Iambic Prices $150M IPO At $16, Pops On Nasdaq DebutIambic Therapeutics priced its IPO at $16 a share, raising $150 million and debuting on Nasdaq under IAM, with shares closing up 18.19% at $18.91 on Thursday after Pulse covered its upsized terms last week.→
- Oct 8, 2026Iambic Therapeutics Sets Terms For $150M Nasdaq IPOIambic Therapeutics set terms for a $150 million Nasdaq IPO at $15-$17 a share, up sharply from the roughly $100 million it originally sought when it filed in September.→
- Sep 24, 2026Precision Neuroscience Hits $1B Valuation On $250M RaisePrecision Neuroscience closed an oversubscribed $250 million Series D co-led by Bill Ackman's Pershing Square and his new Ackman Oxman Institute, valuing the brain-computer interface company at just over $1 billion.→
- Sep 24, 2026Ackman Co-Leads Precision Neuroscience's $250M RoundPrecision Neuroscience closed an oversubscribed $250 million Series D co-led by Bill Ackman's Pershing Square, valuing the brain-computer interface company at just over $1 billion as it scales past 100 patient procedures.→
- Jun 10, 2026SonoThera Raises $125M for Ultrasound Gene TherapySonoThera closed an oversubscribed $125 million Series B led by Vida Ventures to push its ultrasound-delivered, nonviral genetic medicine platform toward its first clinical trial in Duchenne muscular dystrophy in 2027.→
Duquesne Family Office FAQ
What stage does Duquesne Family Office invest at?
In the rounds Value Add VC tracks, Duquesne Family Office's deals were most often Series D (1) and Series A (1).
Who are the partners at Duquesne Family Office?
Duquesne Family Office's partners and team include Stanley Druckenmiller (Chairman and CEO) and Sue Meng (General Counsel), according to SEC EDGAR Schedule 13G and SEC EDGAR Form 13F-HR.
What companies has Duquesne Family Office backed?
Companies Value Add VC tracks as Duquesne Family Office investments include Precision Neuroscience and Fab2.
Where is Duquesne Family Office based?
Duquesne Family Office is headquartered in New York, New York, USA and was founded in 2010, according to SEC EDGAR Schedule 13G and The Motley Fool.
Who does Duquesne Family Office co-invest with most?
In the rounds Value Add tracks, Duquesne Family Office most often invests alongside ARK Invest (1 shared deal), B Capital (1 shared deal), Fundomo Management (1 shared deal), Hanwha Asset Management (1 shared deal), Hitachi Ventures (1 shared deal).
References
researched 2026-10-24Sources & methodologyshow
- GlobeNewswireprimary source1 fact
- SEC EDGAR Form 13F-HRprimary source1 fact
- SEC EDGAR Schedule 13Gprimary source1 fact
- WOWTALEValue Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.